Ok. Here's my brief summary of the conference: the conference had a bit more scientific flavour than SI's usual CCs. SI touched on the superiority of Ryoncil over prior cells that the company had purchased, as well as long term survival benefits, etc.
I don't think there was any new slide used during the conference, so I won't post them again all here to avoid clogging up the board.
New information: SI mentioned that Ryoncil is now listed in all 4 major compendia in the US, and that the company is doing everything it can to bring the product to the children in need of it the most.
There were 2 questions taken and answered at the end.
Q1: Thanks for a great talk and congratulations! Could you comment on paediatric non-responders, why do you think they do not respond?
Answer given by SI:
- Almost all children will respond if they’re provided with more prolonged use of the therapy.
- Unlike Rux or other agents, our therapy, the longer it’s used the more likely it is to induce remission.
- There are only a few true non-responders.
Q2: How many children so far have signed up to receive Ryoncil on product launch and have their insurers agreed to cover the cost?
Answer given by SI:
- Discussions with the insurers have been collegial and very positive
- Expect that most major commercial insurers will support and reimburse fully.
SI didn't answer the more important part of Q2 which is the number of patients, which I'm sure is what most participants wanted to know. He circled around the long term survivability again rather than answering that question.
It leaves me wonder - is that because that information is market sensitive and should be released to the ASX first?
(20min delay)